Immunotherapy has set a new standard in treating Hodgkin lymphoma, showing a 92% survival rate and fewer long-term side effects, with FDA approval anticipated soon. A new treatment that activates the immune system to attack cancer has increased the survival rate for advanced Hodgkin lymphoma to an impressive 92 percent, potentially setting a new standard […]
